Trial · NCT00474240

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

NCT00474240, Phase 2, Completed, Aegerion Pharmaceuticals, Inc.; results first posted 2013-02-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia. Trials, record NCT00474240. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00474240

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
NCT number: NCT00474240
Status: Completed
Phases: Phase 2
Enrollment: 157 participants, actual
Lead sponsor: Aegerion Pharmaceuticals, Inc.
Conditions: Hypercholesterolemia
Interventions: Atorvastatin 20 mg, AEGR-733 5 mg, AEGR-733 10 mg, Placebo, AEGR-733 5 mg + atorvastatin 20 mg, AEGR-733 10 mg + atorvastatin 20 mg
First posted: 2007-05-16
Last updated: 2018-03-20
Results first posted: 2013-02-21
Limitations and caveats: Study AEGR-733-003, initiated in May 2007, was halted, and restarted under an amended Protocol in November 2007.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percent Change From Baseline in LDL-C at 8 Weeks	Atfer 8 weeks on study drug
Secondary	Percent Change From Baseline of Other Lipids	After 8 weeks of study drug

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percent Change From Baseline in LDL-C at 8 Weeks	Atfer 8 weeks on study drug	Intent To Treat	Percent Change	MEAN
SECONDARY	Percent Change From Baseline of Other Lipids	After 8 weeks of study drug	Intent To Treat	Percent	MEAN

Source ClinicalTrials.gov

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Percent Change From Baseline in LDL-C at 8 Weeks	Placebo		2	Standard Deviation 11.2	Percent Change
Percent Change From Baseline in LDL-C at 8 Weeks	Atorvastatin 20 mg		-42	Standard Deviation 16.4	Percent Change
Percent Change From Baseline in LDL-C at 8 Weeks	AEGR-733 5 mg		-16	Standard Deviation 17.3	Percent Change
Percent Change From Baseline in LDL-C at 8 Weeks	AEGR-733 10 mg		-37	Standard Deviation 23.0	Percent Change
Percent Change From Baseline in LDL-C at 8 Weeks	AEGR-733 5 mg + Atorvastatin 20 mg		-47	Standard Deviation 19.2	Percent Change
Percent Change From Baseline in LDL-C at 8 Weeks	AEGR-733 10 mg + Atorvastatin 20 mg		-50	Standard Deviation 28.0	Percent Change
Percent Change From Baseline of Other Lipids	Placebo	Percent change from baseline in total cholesterol	2	Standard Deviation 9.9	Percent
Percent Change From Baseline of Other Lipids	Atorvastatin 20 mg	Percent change from baseline in total cholesterol	-30	Standard Deviation 12.4	Percent
Percent Change From Baseline of Other Lipids	AEGR-733 5 mg	Percent change from baseline in total cholesterol	-18	Standard Deviation 14.6	Percent
Percent Change From Baseline of Other Lipids	AEGR-733 10 mg	Percent change from baseline in total cholesterol	-33	Standard Deviation 19.0	Percent

1 to 10 of 24Source ClinicalTrials.gov

See all 24 results by group

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	27
Overall Study	STARTED	Atorvastatin 20 mg	26
Overall Study	STARTED	AEGR-733 5 mg	26
Overall Study	STARTED	AEGR-733 10 mg	26
Overall Study	STARTED	AEGR-733 5 mg + Atorvastatin 20 mg	26
Overall Study	STARTED	AEGR-733 10 mg + Atorvastatin 20 mg	26
Overall Study	COMPLETED	Placebo	26
Overall Study	COMPLETED	Atorvastatin 20 mg	25
Overall Study	COMPLETED	AEGR-733 5 mg	17
Overall Study	COMPLETED	AEGR-733 10 mg	10

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events174

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrhoea	Gastrointestinal disorders	Placebo	2	27	2
other	Diarrhoea	Gastrointestinal disorders	Atorvastatin 20 mg	2	26	2
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 5 mg	16	26	16
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 10 mg	15	26	15
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 5 mg + Atorvastatin 20 mg	11	26	11
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 10 mg + Atorvastatin 20 mg	20	26	20
other	Nausea	Gastrointestinal disorders	Placebo	1	27	1
other	Nausea	Gastrointestinal disorders	Atorvastatin 20 mg	2	26	2
other	Nausea	Gastrointestinal disorders	AEGR-733 5 mg	5	26	5
other	Nausea	Gastrointestinal disorders	AEGR-733 10 mg	7	26	7

1 to 10 of 174Source ClinicalTrials.gov

See all 174 adverse events

Adverse event totals18

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Atorvastatin 20 mg
Total, all-cause mortality	AEGR-733 5 mg
Total, all-cause mortality	AEGR-733 10 mg
Total, all-cause mortality	AEGR-733 5 mg + Atorvastatin 20 mg
Total, all-cause mortality	AEGR-733 10 mg + Atorvastatin 20 mg
Total, other adverse events	Placebo	17	27
Total, other adverse events	Atorvastatin 20 mg	15	26
Total, other adverse events	AEGR-733 5 mg	23	26
Total, other adverse events	AEGR-733 10 mg	23	26

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
17215532	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00474240

GET https://conductscience.org/api/trials/v1/NCT00474240/results?page=2

API reference For AI assistants